Pavel N. Pichurin, M.D.

Open

• Non-interventional post-authorization study of belzutifan in adult patients with von Hippel-Lindau disease-associated renal cell carcinoma, pancreatic neuroendocrine tumor and/or central nervous system hemangioblastoma Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to characterize the effectiveness of belzutifan for patients with VHL disease-associated RCC and/or CNS hemangioblastoma treated in real-world clinical practice. The primary effectiveness parameter includes tumor reductive procedures given the clinical importance of this parameter and association with subsequent morbidity and mortality of disease.